Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)

Research output: Contribution to journalLiterature review

Abstract

Introduction: The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. Areas covered: All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/or class of compounds along with data (if available) on their inhibitory activity. The presentation is deepened by additional data published in peer-reviewed literature. Expert opinion: Key events that stimulated the search of IDO inhibitors are presented. To date, however, the number of available scaffolds remains limited with only one confirmed inhibitor (from Incyte Corp.) in the clinic. Major challenges in the search for IDO inhibitors are discussed as well as the relevance of selectivity of IDO inhibition versus inhibition of tryptophan 2,3-dioxygenase. © 2013 Informa UK, Ltd.
Original languageEnglish
Pages (from-to)1367-1381
Number of pages15
JournalExpert opinion on therapeutic targets
Volume23
Issue number10
DOIs
Publication statusPublished - 1 Oct 2013

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Scaffolds
Tryptophan Oxygenase
Literature
Patents
Expert Testimony
Immunotherapy
Neoplasms

Keywords

  • cancer, immunotherapy, indoleamine 2,3-dioxygenase, patent review

Cite this

@article{1400b5753331420eacc3de5bf154a95c,
title = "Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)",
abstract = "Introduction: The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. Areas covered: All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/or class of compounds along with data (if available) on their inhibitory activity. The presentation is deepened by additional data published in peer-reviewed literature. Expert opinion: Key events that stimulated the search of IDO inhibitors are presented. To date, however, the number of available scaffolds remains limited with only one confirmed inhibitor (from Incyte Corp.) in the clinic. Major challenges in the search for IDO inhibitors are discussed as well as the relevance of selectivity of IDO inhibition versus inhibition of tryptophan 2,3-dioxygenase. {\circledC} 2013 Informa UK, Ltd.",
keywords = "cancer, immunotherapy, indoleamine 2,3-dioxygenase, patent review",
author = "E. Dolušić and R. Fr{\'e}d{\'e}rick",
year = "2013",
month = "10",
day = "1",
doi = "10.1517/13543776.2013.827662",
language = "English",
volume = "23",
pages = "1367--1381",
journal = "Expert opinion on therapeutic targets",
issn = "1744-7631",
publisher = "Informa Healthcare",
number = "10",

}

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012). / Dolušić, E.; Frédérick, R.

In: Expert opinion on therapeutic targets, Vol. 23, No. 10, 01.10.2013, p. 1367-1381.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)

AU - Dolušić, E.

AU - Frédérick, R.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Introduction: The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. Areas covered: All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/or class of compounds along with data (if available) on their inhibitory activity. The presentation is deepened by additional data published in peer-reviewed literature. Expert opinion: Key events that stimulated the search of IDO inhibitors are presented. To date, however, the number of available scaffolds remains limited with only one confirmed inhibitor (from Incyte Corp.) in the clinic. Major challenges in the search for IDO inhibitors are discussed as well as the relevance of selectivity of IDO inhibition versus inhibition of tryptophan 2,3-dioxygenase. © 2013 Informa UK, Ltd.

AB - Introduction: The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. Areas covered: All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/or class of compounds along with data (if available) on their inhibitory activity. The presentation is deepened by additional data published in peer-reviewed literature. Expert opinion: Key events that stimulated the search of IDO inhibitors are presented. To date, however, the number of available scaffolds remains limited with only one confirmed inhibitor (from Incyte Corp.) in the clinic. Major challenges in the search for IDO inhibitors are discussed as well as the relevance of selectivity of IDO inhibition versus inhibition of tryptophan 2,3-dioxygenase. © 2013 Informa UK, Ltd.

KW - cancer, immunotherapy, indoleamine 2,3-dioxygenase, patent review

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84884545929&partnerID=8YFLogxK

U2 - 10.1517/13543776.2013.827662

DO - 10.1517/13543776.2013.827662

M3 - Literature review

VL - 23

SP - 1367

EP - 1381

JO - Expert opinion on therapeutic targets

JF - Expert opinion on therapeutic targets

SN - 1744-7631

IS - 10

ER -